Obtaining Stable Homogenous Mixtures with Micronized APIs - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Obtaining Stable Homogenous Mixtures with Micronized APIs
The authors examine the use of various grades of direct-compression mannitol in direct-compression tableting process to evaluate the content uniformity of micronized APIs and excipients in a solid-dosage formulation.

Pharmaceutical Technology
Volume 36, Issue 10, pp. 66-72


The reduction of the RSD of the measured API concentrations shows how the mixture approaches homogeneity with rising mixing times (see Figure 1). A time of 30 min was chosen as sufficient to view the mixture of DC-mannitol with micronized ascorbic acid as homogeneous (RSD = 0.67%). The mixing behavior of a blend is dependent on the API and the excipient, as well as on mixer type, scale, and the degree of filling of the mixer. As the latter parameters were constant for all assessed blends, differences in homogeneity must be due to either the API or the excipient. In this case, the micronized hydrophobic particles of riboflavin tend to re-agglomerate during mixing. This re-agglomeration is why at first the homogeneity decreases before the mixture reaches a steady state (see Figure 1).

The resulting mixing time of 30 min seems to be rather high. It has to be taken into account that this small laboratory-scale mixing unit is certainly not optimized. More importantly, however, the micronized API granules have a tendency of agglomeration to each other due to their high surface energy. This binding force has to be broken up and replaced by an alternative binding force—adsorption and van der Vaals interaction–with the carrier surface. This is a dynamic equilibrium process and takes more time than just a statistical distribution of different particles in space.

Figure 3: Comparison of the surface area and pore volumes of different excipients available for direct compression. DC is direct compression. Parkteck M 200 is a proprietary product of DC-grade mannitol (Merck KGaA). Sp is specific.
The comparison of different DC-mannitols at optimum mixing time reveals differences in the homogeneity of such a mixture with micronized ascorbic acid and riboflavin (see Figure 2). Clearly, for a hydrophilic API, the achievable homogeneity is greater than for a hydrophobic API. In this case, the different attraction forces of the hydrophobic API to a hydrophilic carrier cause more API particles to re-agglomerate rather than bind to the carrier surface. This is not a surprising observation because this relationship would be true for all excipients. There are, however, differences in the achievable blend uniformity among the compared carriers. The best homogeneity for both API cases was found for the excipient with the highest surface area, DC-Mannitol M (see Table I). This observation gives a hint for a correlation of BET surface area and/or pore volume to the achievable homogeneity. There also are significant differences between spray-dried and granulated DC-mannitol even having similar BET-surfaces (see Figure 3). The quality of the surface structure, not only the quantitative size of the surface area, seems to be relevant.

To prove an adsorption of the API to the excipient surface with a certain force, the remaining concentration of ascorbic acid and riboflavin was measured after 15 min on an air-jet sieve. By this procedure, a separation of fine API particles from the carrier can be expected if they were not strongly adsorbed. A recovery of 100% would mean a perfectly strong adsorption of the API to the carrier while a recovery of 0% shows no absorption to the carrier.

Figure 4: Comparison of the API concentration measured after 15 min in an air-jet sieve using either granulated direct-compression (DC)-Mannitol B, spray-dried DC-Mannitol A, or DC-mannitol M as excipients for the model drugs of ascorbic acid or riboflavin.
A much stronger adsorption was found for the spray-dried DC-mannitols in comparison to the granulated quality (see Figure 4). For low API concentrations of a hydrophilic drug, both spray-dried mannitols show similar results. Using higher API loads, it was demonstrated that the higher surface area of DC-Mannitol M shows advantages of a higher binding capacity. This effect was confirmed with a hydrophobic API, riboflavin. This finding may again result from the different surface structure of the investigated excipients. The lower recovery of hydrophobic API again confirms a weaker force of surface adsorption by this class of API.

Figure 5: Scanning electron microscope (SEM) image showing a mixture of direct-compression (DC)-mannitol M 200 and micronized ascorbic acid (drug load 1% w/w).
To visualize the API distribution on the excipients' surface, a scanning electron microscope (SEM) was employed. Figure 5 shows the SEM image of a mixture of ascorbic acid and DC-mannitol M. The micronized API particles are readily identifiable due to the different crystal structures of API and carrier (colorization performed manually). The API crystals were found within the pore structure of the much larger excipient particles. Figure 6 shows the SEM image of spray-dried DC-Mannitol A and ascorbic acid. In this case, less areas are present that are suitable for the absorption of the API. The overall surface is less structured. A similar distribution on the excipients' surface was determined for the hydrophobic model drug riboflavin (see Figure 7).

Figure 6: Scanning electron microscope (SEM) image showing a mixture of spray-dried direct compression (DC)-Mannitol A and micronized ascorbic acid (drug load 1% w/w).
The importance of the surface area and the pore volume of an excipient for the homogeneity of the mixture was demonstrated. In the next step, the surface area and porosity of various excipients available for direct compression were analyzed using the BET method (nitrogen adsorption). As the API is adsorbed to a porous surface, the observed differences of the excipients may give rise to a different behavior in the adsorption of the micronized APIs (see Figure 3).

Figure 7: Mixture of direct-compression (DC)- mannitol M 200 with micronized riboflavin (drug load 1% w/w). Light microscope with 40 x magnification. The yellow particles of the API are clearly visible in the porosity of the carrier surface.
This study showed that stable mixtures of much smaller micronized API particles with DC-excipients can be achieved. The next question examined was whether this approach was suitable for the DC process for an actual formulation.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here